Two New Promising Additions to our SWI "QuickPicks Portfolio"
Strong Buy Recommendations by Eleven Analysts 
Los Angeles, March 30, 2017 - Today SWI announces two new additions to its biotech "QuickPicks Portfolio" backed with strong buy recommendation by eleven third party analysts; Retrophin, Inc (NASDAQ:RTX) and Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX). The SWI QuickPicks Portfolio has a track record of consistently outperforming all leading major indices. 

 Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company¬ís product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California
 RTRX  is trading at $17.76 at the close of market Friday
Three Strong Buy Recommendations
Price Target is $33.33
  Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, and Merck KGaA and Pfizer; collaborative research and development agreement with National Cancer Institute; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

SNDX is trading at $13.22 at the close of market Friday
Eight Strong Buy Recommendations
Price Target is $27.13

If you want to follow all other companies that we cover with more in depth research reports, go to our research site at www.swiresearch.com/report-index to download the reports,
or visit
www.stockwatchindex.com for up to date news on the covered companies.
Please feel free to
re-distribute the reports to your friends and colleagues.
Rainer Poertner - Chief Analyst
S tockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided.  SWI has not been compensated for this report, but may hold or plan to acquire positions of every stock in this report for its portfolio a nd reserves the right to buy or sell positions at its sole  discretion. The included information is subject to change without notice. Please visit  www.swiresearch.com/#!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.